Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A twelve-month study of nelfinavir (Viracept) in women has begun enrollment. The study will test the protease inhibitor's effectiveness in combination with saquinavir, d4T, and 3TC in women with viral loads greater than 10,000. HIV levels in both blood and vaginal secretions will be measured. Enrollment information is provided.
 ...
PMID:Women's nelfinavir (Viracept) trial. 1136 33

The Food and Drug Administration (FDA) warns that the antihistamine terfenadine, found in Seldane and Seldane-D, cannot be taken with Crixivan, Norvir, Invirase, Fortovase, and Viracept. Taking terfenadine products with these anti-HIV drugs can lead to a potentially fatal heart condition. The FDA formerly suggested taking the drug off the market and replacing it with Allegra (faxofenadine hydrochloride), a safer drug.
 ...
PMID:Seldane warnings. 1136 51

Anti-HIV therapy research continues to show promising results and a research update is presented on the following antiviral topics: efavirenz (DMP 266, Sustiva), indinavir (Crixivan), indinavir plus ritonavir (Norvir), hard vs. soft gel saquinavir, nelfinavir (Viracept) cross-resistance, and T-20 (pentafuside). Tables present regimen results, including viral load drop and CD4 cell increases. Difficulties in preventing viral resistance are also discussed. Situations to avoid include using dosing schedules that do not sufficiently suppress the virus, waiting for viral load to return to pre-treatment levels before switching drugs, and not switching drugs to at least two new potent compounds when changing combination therapy. The challenge for patients who have failed previous drug therapies is to develop strategies that allow them to extend the effectiveness of their options long enough for at least two new potent drugs to become available.
 ...
PMID:Update on antivirals. 1136 81

The number of people joining research studies has dropped since stronger and more effective anti-HIV drugs have been manufactured and approved. However, trials are still enrolling people who are not doing well on their current treatments. Information about trials for people who are failing nelfinavir (Viracept) or indinavir (Crixivan) and the eligibility criteria for many of these studies are provided. Several studies for people who have failed one or more treatments are in the planning stages.
 ...
PMID:Other options: clinical trials. 1136 20

Many of the presentations at the 5th Conference on Retroviruses and Opportunistic Infections were prompted by great successes in treating HIV. There are now more than 300 possible drug combinations, and many promising drugs are under development. Results of tests of several drugs, individually and in combination, are presented. Nucleoside analogs, generally in triple combinations, were well tolerated and led to undetectable viral loads. Crixivan is as effective in twice-daily doses as it is in the FDA-mandated three-times-a-day regimen. People with advanced HIV did better when they started with triple combinations with Crixivan, than those with advanced HIV who started on dual therapy or monotherapy. Viracept treatment resulted in undetectable viral loads in up to 92 percent of the participants in a study group. There are several studies underway to test the safety and effectiveness of combinations that include two protease inhibitors. Two experimental drugs, FTC and hydroxyurea (HU), were noted as having strong potential for HIV treatment.
 ...
PMID:Update from the 5th Conference on Retroviruses and Opportunistic Infections. 1136 83

Several clinical trials are underway for both adults and children. ACTG 377 is studying four different drug combinations in pediatric patients up to 17 years of age. The drugs are 3TC (Epivir, lamivudine), d4T (Zerit, stavudine), nelfinavir (Viracept), nevirapine (Viramune), and ritonavir (Norvir). The Phase I/II study is testing for safety and efficacy. FDA 285A is studying the experimental second generation protease inhibitor ABT-378, in combination with ritonavir and 3TC or d4T. Researchers at the National Institutes of Health (NIH) are studying the effectiveness of once-daily dosing of ddI in combination with d4T, in treatment-naive people, and they are also pursuing a study to determine where HIV hides in the body. Enrollment criteria and contact information are included for each study.
 ...
PMID:Drug studies for children and adults. 1136 82

Little research has been done on the interaction of various anti-HIV drugs and birth control pills. Contraceptive levels decrease with the introduction of some protease inhibitors such as Norvir (ritonavir) or Viracept (nelfinavir). Studies suggest that if a woman is taking both antiretroviral drugs and birth control pills she should discuss increasing the birth control dosage and/or using other means of preventing pregnancy with her doctor.
 ...
PMID:Pregnant pause. 1136 43

The AIDS Clinical Trials Group (ACTG) is preparing two trials for persons who are on a protease inhibitor regimen that has failed. ACTG 398 will use the experimental drug, amprenavir (141W94), in addition to three drugs from different anti-HIV medication classes, and possibly one other protease inhibitor. ACTG 400 is for people whose viral load is greater than 1,000 after 16 weeks of treatment with Viracept (Nelfinavir). Some exclusion criteria are listed. Contact information is provided.
 ...
PMID:Trials for protease failure. 1136 84

Dr. Charles Flexner, an Associate Professor at Johns Hopkins University, discusses different issues involving drug interactions. Flexner states that some interactions exist between street drugs and HIV medications, including between benzodiazepines and Ritonavir (Norvir) or Nelfinavir (Viracept). He also reports on toxicity and death cases associated with MDMA (ecstasy) and protease inhibitors. Drugs for opportunistic infections are also described; most are not implicated in clinically significant drug interactions, nor are most over-the-counter medications. Dr. Flexner's opinions on protease-sparing regimens and lipodystrophy are also provided.
 ...
PMID:Double jeopardy: the hazards of drug-drug interactions. 1136 84

The 38th Interscience Conference on Antimicrobial Agents and Chemotherapy featured information on new antiretroviral treatments, changes in dosing, and new vaccine information. Adefovir dipivoxil (Preveon) is a new nucleoside reverse transcriptase inhibitor that is administered once daily. A study of adefovir dipivoxil is described and the side effects are detailed. A clinical trial of the protease inhibitor Nelfinavir (Viracept) has shown that dosing twice a day may be as effective as the currently prescribed three times a day. Since lower dosing tends to increase a patient's adherence to treatment, it may have a long-term positive effect on treating HIV. Other drug treatments and possible changes in dosing are presented. A pneumococcal vaccine study is described, and it was found that the vaccine did not lead to an increase in viral load. Immunization against Pneumococcus is suggested for all adults who are HIV-infected.
 ...
PMID:Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference. 1136 34


<< Previous 1 2 3 4 Next >>